US Bancorp DE Purchases Shares of 2,658 Entrada Therapeutics, Inc. (NASDAQ:TRDA)

US Bancorp DE purchased a new stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) during the third quarter, Holdings Channel reports. The firm purchased 2,658 shares of the company’s stock, valued at approximately $42,000.

A number of other large investors have also added to or reduced their stakes in TRDA. Acadian Asset Management LLC purchased a new stake in Entrada Therapeutics during the first quarter valued at about $79,000. SG Americas Securities LLC bought a new position in shares of Entrada Therapeutics during the third quarter valued at about $156,000. Allspring Global Investments Holdings LLC grew its stake in shares of Entrada Therapeutics by 87.2% during the second quarter. Allspring Global Investments Holdings LLC now owns 27,631 shares of the company’s stock valued at $394,000 after buying an additional 12,868 shares during the last quarter. BayBridge Capital Group LLC bought a new position in shares of Entrada Therapeutics during the third quarter valued at about $464,000. Finally, Rhumbline Advisers grew its stake in shares of Entrada Therapeutics by 25.3% during the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after buying an additional 7,452 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Price Performance

NASDAQ TRDA opened at $17.85 on Monday. The stock has a market capitalization of $667.95 million, a PE ratio of 11.23 and a beta of -0.26. Entrada Therapeutics, Inc. has a 1 year low of $10.75 and a 1 year high of $20.49. The business’s 50-day moving average is $16.76 and its 200 day moving average is $15.94.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TRDA. HC Wainwright raised their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Oppenheimer raised their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th.

Insider Buying and Selling

In related news, CFO Kory James Wentworth sold 8,637 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $19.98, for a total value of $172,567.26. Following the sale, the chief financial officer now directly owns 73,849 shares of the company’s stock, valued at $1,475,503.02. This trade represents a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Natarajan Sethuraman sold 2,642 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $15.09, for a total value of $39,867.78. Following the completion of the sale, the insider now directly owns 183,816 shares in the company, valued at $2,773,783.44. The trade was a 1.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,933 shares of company stock valued at $410,816 over the last ninety days. 7.59% of the stock is owned by insiders.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.